ArticlePrzeglad gastroenterologiczny2026
Study of serum long non-coding RNA interferon gamma antisense-1 as a biomarker of activity in Crohn's disease.
Article in Przeglad gastroenterologiczny, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Crohn's disease is a chronic inflammatory bowel disease that can result in progressive bowel damage and disability. Also, Crohn's disease can affect individuals of any age, from children to the elderly, and may cause significant morbidity and impact quality of life. LncRNAs are transcripts consisting of more than 200 nucleotides that can be processed by RNA polymerase II. Aim: The aim of this study was to assess the role of serum lncRNA (IFNG-AS1) as a marker of disease activity in patients with Crohn's disease. Material and methods: The study included 50 subjects divided into the following groups: Group I: Thirty patients with Crohn's disease, subdivided into: Group Ia; 15 patients with active Crohn's disease. Group Ib; 15 patients with Crohn's disease in remission. Group II: 20 subjects as control group. Detailed history taking, systemic physical examination, laboratory investigations, and relative quantification of serum level of lncRNA IFNG-AS1: real-time PCR was performed in all patients. Results: The mean IFN-G AS1 (2-∆∆ cT) level in group I was (70.10 ±150.55 pg/ml) markedly higher than the mean in group II (0.70 ±0.34 pg/ml). The mean in group Ia had significantly higher IFN-G AS1 (2-∆∆ cT) compared to group Ib ( Conclusions: Serum IFNG AS-1 can be a good diagnostic marker and can be used to measure disease activity in Crohn's disease patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.